Treating tobacco dependence: State of the science and new directions

Journal of Clinical Oncology

Volumn 23, Issue 2, 2005, Pages 311-323

  Lerman, Caryn ^a   Patterson, Freda ^a   Berrettini, Wade ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; BACLOFEN; CLONIDINE; COCAINE; FLUOXETINE; MORPHINE; NALTREXONE; NICOTINE; PLACEBO; REBOXETINE;

BURNING SENSATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG FORMULATION; ERYTHEMA; EYE IRRITATION; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; META ANALYSIS; MOOD DISORDER; NAUSEA; NONHUMAN; PATIENT COUNSELING; PHARMACOGENETICS; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; TOBACCO DEPENDENCE; TREATMENT INDICATION; VOMITING; WATERY EYE; FEMALE; FOOD AND DRUG ADMINISTRATION; FORECASTING; NEOPLASM; PSYCHOLOGICAL ASPECT; SMOKING CESSATION; UNITED STATES;

FEMALE; FORECASTING; HUMANS; NEOPLASMS; PHARMACOGENETICS; PREGNANCY; SMOKING CESSATION; TOBACCO USE DISORDER; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 13744250667     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.058     Document Type: Review

References (174)

1. American Cancer Society: Cancer Facts and Figures, 2004, http://www.cancer.org/docroot/STT/stt_0.asp
2. Cinciripini P, Gritz ER, Tsoh J, et al: Smoking cessation and cancer prevention, in Holland J (ed): Psycho-onclogy. New York, Oxford University Press, 1998
3. Cigarette smoking among adults-United States, 2000. MMWR Morb Mortal Wkly Rep 51:642-645, 2002
4. Haxby DG: Treatment of nicotine dependence. Am J Health Syst Pharm 52:265-281, 1995
5. Fiore MC, Bailey W, Cohen S: Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, MD, US Department of Health and Human Services, Public Health Service, 2000
6. Fiore MC, Novotny TE, Pierce JP, et al: Methods used to quit smoking in the United States. Do cessation programs help? JAMA 263:2760-2765, 1990
7. Cunningham JA, Ferrence R, Cohen J, et al: Interest in self-help materials among a general population sample of smokers. Addict Behav 28:811-816, 2003
8. Prochazka AV: New developments in smoking cessation. Chest 117:169S-175S, 2000
9. Coleman T: ABC of smoking cessation. Use of simple advice and behavioural support. BMJ 328:397-399, 2004
10. Curry SJ, McBride C, Grothaus LC, et al: A randomized trial of self-help materials, personalized feedback, and telephone counseling with nonvolunteer smokers. J Consult Clin Psychol 63:1005-1014, 1995
11. Prochaska JO, DiClemente CC, Velicer WF, et al: Standardized, individualized, interactive, and personalized self-help programs for smoking cessation. Health Psychol 12:399-405, 1993
12. Fiore MC, Kenford SL, Jorenby DE, et al: Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments. Chest 105:524-533, 1994
13. Simon JA, Carmody TP, Hudes ES, et al: Intensive smoking cessation counseling versus minimal counseling among hospitalized smokers treated with transdermal nicotine replacement: a randomized trial. Am J Med 114:555-562, 2003
14. Jorenby DE, Smith SS, Fiore MC, et al: Varying nicotine patch dose and type of smoking cessation counseling. JAMA 274:1347-1352, 1995
15. Zhu SH, Stretch V, Balabanis M, et al: Telephone counseling for smoking cessation: effects of single-session and multiple-session interventions. J Consult Clin Psychol 64:202-211, 1996
16. Daughton DM, Heatley SA, Prendergast JJ, et al: Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. A randomized, placebo-controlled, double-blind study. Arch Intern Med 151:749-752, 1991
17. Silagy C, Lancaster T, Stead L, et al: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev: CD000146, 2004
18. Hughes JR: Pharmacotherapy for smoking cessation: unvalidated assumptions, anomalies, and suggestions for future research. J Consult Clin Psychol 61:751-760, 1993
19. Niaura R, Bock B, Goldstein MG, et al: Treating nicotine dependence: pharmacological and behavioral approaches, in Rommelspacher H, Schuckit MA (eds): Drugs of Abuse (International Practice and Research - Bailliere's Clinical Psychiatry). St Louis, MO, Elsevier, 1996
20. Henningfield JE: Nicotine medications for smoking cessation. N Engl J Med 333:1196-1203, 1995
21. Rose JE: Nicotine addiction and treatment. Annu Rev Med 47:493-507, 1996
22. Silagy C, Mant D, Fowler G, et al: Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 343:139-142, 1994
23. Hughes JR, Gust SW, Keenan RM, et al: Nicotine vs placebo gum in general medical practice. JAMA 261:1300-1305, 1989
24. Silagy C, Lancaster T, Stead L, et al: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev: CD000146, 2002
25. Garvey AJ, Kinnunen T, Nordstrom BL, et al: Effects of nicotine gum dose by level of nicotine dependence. Nicotine Tob Res 2:53-63, 2000
26. Sachs DP: Effectiveness of the 4-mg dose of nicotine polacrilex for the initial treatment of high-dependent smokers. Arch Intern Med 155:1973-1980, 1995
27. Tonnesen P, Fryd V, Hansen M, et al: Effect of nicotine chewing gum in combination with group counseling on the cessation of smoking. N Engl J Med 318:15-18, 1988
28. Fant RV, Owen LL, Henningfield JE: Nicotine replacement therapy. Prim Care 26:633-652, 1999
29. Pierce JP, Gilpin EA: Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA 288:1260-1264, 2002
30. Silagy C, Mant D, Fowler G, et al: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev: CD000146, 2000
31. Shiffman S, Hughes JR, Di Marino ME, et al: Patterns of over-the-counter nicotine gum use: persistent use and concurrent smoking. Addiction 98:1747-1753, 2003
32. Fiore MC, Smith SS, Jorenby DE, et al: The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA 271:1940-1947, 1994
33. Lewis SF, Piasecki TM, Fiore MC, et al: Transdermal nicotine replacement for hospitalized patients: a randomized clinical trial. Prev Med 27:296-303, 1998
34. Hurt RD, Dale LC, Fredrickson PA, et al: Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. JAMA 271:595-600, 1994
35. Daughton DM, Fortmann SP, Glover ED, et al: The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day. Prev Med 28:113-118, 1999
36. Tonnesen P, Norregaard J, Simonsen K, et al: A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. N Engl J Med 325:311-315, 1991
37. Kenford SL, Fiore MC, Jorenby DE, et al: Predicting smoking cessation. Who will quit with and without the nicotine patch. JAMA 271:589-594, 1994
38. Shiffman S, Gorsline J, Gorodetzky CW: Efficacy of over-the-counter nicotine patch. Nicotine Tob Res 4:477-483, 2002
39. Dale LC, Hurt RD, Offord KP, et al: High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. JAMA 274:1353-1358, 1995
40. Hughes JR, Lesmes GR, Hatsukami DK, et al: Are higher doses of nicotine replacement more effective for smoking cessation? Nicotine Tob Res 1:169-174, 1999
41. Silagy C, Mant D, Fowler G, et al: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev: CD000146, 2001
42. Fiore M, Smith S, Jorenby D, et al: The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA 271:1940-1947, 1994
43. Tonnesen P, Paoletti P, Gustavsson G, et al: Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J 13:238-246, 1999
44. Bolin LJ, Follette WC, Antonuccio DO, et al: Transdermal nicotine: The long and short of it. Psychol Addict Behav 13:152-156, 1999
45. Stapleton J, Russel M, Feyerabend C: Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction 90:31-42, 1995
46. Pomerleau OF, Pomerleau CS, Marks JL, et al: Prolonged nicotine patch use in quitters with past abstinence-induced depressed mood. J Subst Abuse Treat 24:13-18, 2003
47. Schneider NG, Olmstead R, Mody FV, et al: Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction 90:1671-1682, 1995
48. Henningfield JE, Keenan RM: Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 61:743-750, 1993
49. Hurt R, Dale L, Croghan G, et al: Nicotine nasal spray for smoking cessation: pattern of use, side effects, relief of withdrawal symptoms, and cotinine levels. Mayo Clin Proc 73:118-125, 1998
50. Blondal T, Franzon M, Westin A: A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation. Eur Respir J 10:1585-1590, 1997
51. Hjalmarson A, Franzon M, Westin A, et al: Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study. Arch Intern Med 154:2567-2572, 1994.
52. Sutherland G, Russell MA, Stapleton J, et al: Nasal nicotine spray: a rapid nicotine delivery system. Psychopharmacology (Berl) 108:512-518, 1992
53. Hajek P, West R, Foulds J, et al: Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 159:2033-2038, 1999
54. Croghan GA, Sloan JA, Croghan IT, et al: Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting. Nicotine Tob Res 5:181-187, 2003
55. Lerman C, Kaufmann V, Rukstalis M, et al: Individualizing nicotine replacement therapy for the treatment of tobacco dependence. Ann Intern Med 140:426-433, 2004
56. Kaufmann V, Jepson C, Rukstalis M, et al: Subjective effects of an initial dose of nicotine nasal spray predict treatment outcome. Psychopharmacology (Berl) 172:271-276, 2004
57. Hughes JR: Motivating and helping smokers to stop smoking. J Gen Intern Med 18:1053-1057, 2003
58. Tonnesen P, Norregaard J, Mikkelsen K, et al: A double-blind trial of a nicotine inhaler for smoking cessation. JAMA 269:1268-1271, 1993
59. Schneider NG, Olmstead R, Nilsson F, et al: Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. Addiction 91:1293-1306, 1996
60. Hjalmarson A, Nilsson F, Sjostrom L, et al: The nicotine inhaler in smoking cessation. Arch Intern Med 157:1721-1728, 1997
61. West R, Hajek P, Nilsson F, et al: Individual differences in preferences for and responses to four nicotine replacement products. Psychopharmacology (Berl) 153:225-230, 2001
62. Choi JH, Dresler CM, Norton MR, et al: Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res 5:635-644, 2003
63. Shiffman S, Dresler CM, Hajek P, et al: Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 162:1267-1276, 2002
64. Muramoto ML, Ranger-Moore J, Leischow SJ: Efficacy of oral transmucosal nicotine lozenge for suppression of withdrawal symptoms in smoking abstinence. Nicotine Tob Res 5:223-230, 2003
65. Shiffman S, Dresler CM, Rohay JM: Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy. Addiction 99:83-92, 2004
66. Ascher JA, Cole JO, Colin JN, et al: Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56:395-401, 1995
67. Cooper BR, Wang CM, Cox RF, et al: Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 11:133-141, 1994
68. Sanchez C, Hyttel J: Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19:467-489, 1999
69. Slemmer JE, Martin BR, Damaj MI: Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321-327, 2000
70. Tonnesen P, Tonstad S, Hjalmarson A, et al: A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med 254:184-192, 2003
71. Dalsgareth OJ, Hansen NC, Soes-Petersen U, et al: A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. Nicotine Tob Res 6:55-61, 2004
72. Jorenby DE, Leischow SJ, Nides MA, et al: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685-691, 1999
73. Gold PB, Rubey RN, Harvey RT: Naturalistic, self-assignment comparative trial of bupropion SR, a nicotine patch, or both for smoking cessation treatment in primary care. Am J Addict 11:315-331, 2002
74. Hurt RD, Sachs DP, Glover ED, et al: A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1195-1202, 1997
75. Hays JT, Hurt RD, Rigotti NA, et al: Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann Intern Med 135:423-433, 2001
76. Gonzales D, Bjornson W, Durcan MJ, et al: Effects of gender on relapse prevention in smokers treated with bupropion SR. Am J Prev Med 22:234-239, 2002
77. Collins B, Wileyto P, Patterson F, et al: Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling. Nicotine Tob Res 6:27-37, 2004
78. Ahluwalia JS, Harris KJ, Catley D, et al: Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA 288:468-474, 2002
79. Dale LC, Glover ED, Sachs DP, et al: Bupropion for smoking cessation: predictors of successful outcome. Chest 119:1357-1364, 2001
80. US Department of Health and Human Services: The health consequences of smoking: Nicotine addiction. Washington DC, US Government Printing Office, 1990
81. Ward MM, Swan GE, Jack LM: Self-reported abstinence effects in the first month after smoking cessation. Addict Behav 26:311-327, 2001
82. Klesges RC, Winders SE, Meyers AW, et al: How much weight gain occurs following smoking cessation? A comparison of weight gain using both continuous and point prevalence abstinence. J Consult Clin Psychol 65:286-291, 1997
83. Lerman C, Roth D, Kaufmann V, et al: Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend 67:219-223, 2002
84. Lerman C, Niaura R, Collins B, et al: Effect of bupropion on depression symptoms in a smoking cessation clinical trial. Psychol Addict Behav: in press
85. Anton RF, Swift RM: Current pharmacotherapies of alcoholism: A U.S. Perspective. Am J Addict 12:S53-S68, 2003 (suppl 1)
86. Gorelick DA, Rose J, Jarvik ME: Effect of naloxone on cigarette smoking. J Subst Abuse 1:153-159, 1988
87. Karras A, Kane JM: Naloxone reduces cigarette smoking. Life Sci 27:1541-1545, 1980
88. Palmer R, Berens A: Double blind study of the effect of Naloxone on the pleasure of smoking. Fed Proc 42:654, 1983
89. Nemeth-Coslett R, Griffiths RR: Naloxone does not affect cigarette smoking. Psychopharmacology (Berl) 89:261-264, 1986
90. Wewers ME, Dhatt R, Tejwani GA: Naltrexone administration affects ad libitum smoking behavior. Psychopharmacology (Berl) 140:185-190, 1998
91. Hutchison KE, Monti PM, Rohsenow DJ, et al: Effects of naltrexone with nicotine replacement on smoking cue reactivity: preliminary results. Psychopharmacology (Berl) 142:139-143, 1999
92. Sutherland G, Stapleton JA, Russell MA, et al: Naltrexone, smoking behaviour and cigarette withdrawal. Psychopharmacology (Berl) 120:418-425, 1995
93. David S, Lancaster T, Stead LF: Opioid antagonists for smoking cessation. Cochrane Database Syst Rev: CD003086, 2001
94. Wong GY, Wolter TD, Croghan GA, et al: A randomized trial of naltrexone for smoking cessation. Addiction 94:1227-1237, 1999
95. Ahmadi J, Ashkani H, Ahmadi M, et al: Twenty-four week maintenance treatment of cigarette smoking with nicotine gum, clonidine and naltrexone. J Subst Abuse Treat 24:251-255, 2003
96. Covey LS, Glassman AH, Stetner F: Naltrexone effects on short-term and long-term smoking cessation. J Addict Dis 18:31-40, 1999
97. Krishnan-Sarin S, Meandzija B, O'Malley S: Naltrexone and nicotine patch smoking cessation: a preliminary study. Nicotine Tob Res 5:851-857, 2003
98. O'Malley S: Understanding and addressing risk factors for treatment failure. Proceedings of the 9th Annual Meeting of Society of Research in Nicotine and Tobacco 7: 2003 (abstr sym 50)
99. King A, Chilton E, Hatsukami D, et al: Efficacy of naltrexone in smoking cessation: Effects of gender on clinical response. Proceedings of the 9th annual meeting of Society of Research in Nicotine and Tobacco 32: 2003 (abstr PA 8-6)
100. Oslin DW, Berrettini W, Kranzler HR, et al: A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28:1546-1552, 2003
101. Lerman C, Wileyto EP, Patterson F, et al: The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 4:184-192, 2004
102. Hughes JR, Stead LF, Lancaster T: Anti-depressants for smoking cessation. Cochrane Database Syst Rev: CD000031, 2003
103. Cook JW, Spring B, McChargue DE, et al: Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial. Psychopharmacology (Berl) 173:153-159, 2004
104. Hitsman B, Spring B, Borrelli B, et al: Influence of antidepressant pharmacotherapy on behavioral treatment adherence and smoking cessation outcome in a combined treatment involving fluoxetine. Exp Clin Psychopharmacol 9:355-362, 2001
105. Niaura R, Spring B, Borrelli B, et al: Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment. J Consult Clin Psychol 70:887-896, 2002
106. Spring B, Wurtman J, Wurtman R, et al: Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation. Am J Clin Nutr 62:1181-1187, 1995
107. Blondal T, Gudmundsson LJ, Tomasson K, et al: The effects of fluoxetine combined with nicotine inhalers in smoking cessation-a randomized trial. Addiction 94:1007-1015, 1999
108. Browman GP, Wong G, Hudson I, et al: Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med 328:159-163, 1993
109. Duffy SA, Terrell JE, Valenstein M, et al: Effect of smoking, alcohol, and depression on the quality of life of head and neck cancer patients. Gen Hosp Psychiatry 24:140-147, 2002
110. Khuri FR, Kim ES, Lee JJ, et al: The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 10:823-829, 2001
111. Kawahara M, Ushijima S, Kamimori T, et al: Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in Japan: the role of smoking cessation. Br J Cancer 78:409-412, 1998
112. Pinto BM, Eakin E, Maruyama NC: Health behavior changes after a cancer diagnosis: what do we know and where do we go from here? Ann Behav Med 22:38-52, 2000
113. Schnell RA, Malstrom M, James C, et al: Correlates of tobacco use among smokers and recent quitters diagnosed with cancer. Patient Educ Couns 46:137-145, 2002
114. Brandon TH: Behavioral tobacco cessation treatments: yesterday's news or tomorrow's headlines? J Clin Oncol 19:64S-68S, 2001
115. Sarna LP, Brown JK, Lillington L, et al: Tobacco interventions by oncology nurses in clinical practice: report from a national survey. Cancer 89:881-889, 2000
116. Schnoll RA, Rothman RL, Lerman C, et al: Comparing cancer patients who enroll in a smoking cessation program at a comprehensive cancer center with those who decline enrollment. Head Neck 26:278-286, 2004
117. Gritz ER, Carr CR, Rapkin D, et al: Predictors of long-term smoking cessation in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev 2:261-270, 1993
118. Griebel B, Wewers ME, Baker CA: The effectiveness of a nurse-managed minimal smoking-cessation intervention among hospitalized patients with cancer. Oncol Nurs Forum 25:897-902, 1998
119. Wewers ME, Bowen JM, Stanislaw AE, et al: A nurse-delivered smoking cessation intervention among hospitalized postoperative patients-influence of a smoking-related diagnosis: a pilot study. Heart Lung 23:151-156, 1994
120. Stanislaw AE, Wewers ME: A smoking cessation intervention with hospitalized surgical cancer patients: a pilot study. Cancer Nurs 17:81-86, 1994
121. US Department of Health and Human Services: Women and Smoking: A report of the Surgeon General. Rockville, MD, Public Health Service, Office of the Surgeon General, 2001
122. LeClere FB, Wilson JB: Smoking behavior of recent mothers, 18-44 years of age, before and after pregnancy: United States, 1990. Adv Data: 1-11, 1997
123. Fingerhut LA, Kleinman JC, Kendrick JS: Smoking before, during, and after pregnancy. Am J Public Health 80:541-544, 1990
124. Husten CG, Chrismon JH, Reddy MN: Trends and effects of cigarette smoking among girls and women in the United States, 1965-1993. J Am Med Womens Assoc 51:11-18, 1996
125. DiClemente CC, Dolan-Mullen P, Windsor RA: The process of pregnancy smoking cessation: implications for interventions. Tob Control 9:III16-III21, 2000 (suppl 3)
126. McBride CM, Pirie PL: Postpartum smoking relapse. Addict Behav 15:165-168, 1990
127. Orleans CT, Johnson RW, Barker DC, et al: Helping pregnant smokers quit: meeting the challenge in the next decade. West J Med 174:276-281, 2001
128. Melvin CL, Dolan-Mullen P, Windsor RA, et al: Recommended cessation counselling for pregnant women who smoke: a review of the evidence. Tob Control 9:III80-III84, 2000 (suppl 3)
129. Walsh RA, Redman S, Brinsmead MW, et al: A smoking cessation program at a public antenatal clinic. Am J Public Health 87:1201-1204, 1997
130. Secker-Walker RH, Solomon LJ, Flynn BS, et al: Reducing smoking during pregnancy and postpartum: physician's advice supported by individual counseling. Prev Med 27:422-430, 1998
131. Ershoff DH, Quinn VP, Boyd NR, et al: The Kaiser Permanente prenatal smoking-cessation trial: when more isn't better, what is enough? Am J Prev Med 17:161-168, 1999
132. Benowitz NL, Dempsey DA, Goldenberg RL, et al: The use of pharmacotherapies for smoking cessation during pregnancy. Tob Control 9:11191-11194, 2000 (suppl 3)
133. Fiore MC: Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. Respir Care 45:1196-1199, 2000
134. Transdermal Nicotine Study Group: Transdermal nicotine for smoking cessation: Six-month results from two multicenter controlled trials. JAMA 266:3133-3138, 1991
135. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491, 1999
136. Poolsup N, Li Wan Po A, Knight TL: Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther 25:197-220, 2000
137. Lerman C, Niaura R: Applying genetic approaches to the treatment of nicotine dependence. Oncogene 21:7412-7420, 2002
138. Lerman C, Shields P, Wileyto E, et al: Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 12:627-634, 2002
139. Kirchheiner J, Klein C, Meineke I, et al: Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13:619-626, 2003
140. Miksys S, Lerman C, Shields PG, et al: Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 45:122-132, 2003
141. Lerman C, Shields PG, Wileyto EP, et al: Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 22:541-548, 2003
142. Comings D, Ferry L, Bradshaw-Robinson S, et al: The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics 6:73-79, 1996
143. Lerman C, Audrain J, Main D, et al: Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 18:14-20, 1999
144. Sabol S, Nelson M, Fisher C, et al: A genetic association for cigarette smoking behavior. Health Psychol 18:7-13, 1999
145. Spitz M, Shi H, Yang F, et al: Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst 90:358-363, 1998
146. Epstein LH, Jaroni JL, Paluch RA, et al: Dopamine Transporter Genotype as a Risk Factor for Obesity in African-American Smokers. Obes Res 10:1232-1240, 2002
147. Noble EP: D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet 1166:103-125, 2003
148. Thompson J, Thomas N, Singleton A, et al: D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7:479-484, 1997
149. Ritchie T, Noble EP: [3H]naloxone binding in the human brain: alcoholism and the Taq1 A D2 dopamine receptor polymorphism. Brain Res 718:193-197, 1996
150. Noble EP, Blum K, Ritchie T, et al: Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 48:648-654, 1991
151. Anokhin AP, Todorov AA, Madden PA, et al: Brain event-related potentials, dopamine D2 receptor gene polymorphism, and smoking. Genet Epidemiol 17:S37-S42, 1999 (suppl 1)
152. Blum K, Braverman ER, Dinardo MJ, et al: Prolonged P300 latency in a neuropsychiatric population with the D2 dopamine receptor A1 allele. Pharmacogenetics 4:313-322, 1994
153. Noble EP: The DRD2 gene in psychiatric and neurological disorders and its phenotypes. Pharmacogenomics 1:309-333, 2000
154. Fuke S, Suo S, Takahashi N, et al: The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J 1:152-156, 2001
155. Heinz A, Goldman D, Jones DW, et al: Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22:133-139, 2000
156. David SP, Niaura R, Papandonatos GD, et al: Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine Tob Res 5:935-942, 2003
157. Cinciripini P, Wetter D, Tomlinson G, et al: The effects of the DRD2 polymorphism on smoking cessation and negative affect: Evidence for a pharmacogenetic effect on mood. Nicotine Tob Res 6:229-239, 2004
158. Lerman C, Berrettini W, Pinto A, et al: Changes in food reward following smoking cessation: a pharmacogenetic investigation. Psychopharmacology (Berl) 174:571-577, 2004
159. Johnstone EC, Yudkin PL, Hey K, et al: Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 14:83-90, 2004
160. Yudkin P, Munafò M, Hey K, et al: Effectiveness of nicotine patches in relation to genotype in women versus men: Randomised controlled trial. BMJ 328:989-990, 2004
161. Balfour DJ: Neuroplasticity within the mesoaccumbens dopamine system and its role in tobacco dependence. Curr Drug Targets CNS Neurol Disord 1:413-421, 2002
162. Lerman C, Wileyto EP, Patterson F, et al: The functional mu opiod receptor (OPRM1) Asn40Asp variant predicts response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 4:184-192, 2004
163. Zadina JE, Hackler L, Ge LJ, et al: A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386:499-502, 1997
164. Boyadjieva NI, Sarkar DK: The secretory response of hypothalamic beta-endorphin neurons to acute and chronic nicotine treatments and following nicotine withdrawal. Life Sci 61:PL59-PL66, 1997
165. Davenport KE, Houdi AA, Van Loon GR: Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. Neurosci Lett 113:40-46, 1990
166. Bond C, LaForge KS, Tian M, et al: Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 95:9608-9613, 1998
167. Crowley JJ, Oslin DW, Patkar AA, et al: A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr Genet 13:169-173, 2003
168. Paterson NE, Froestl W, Markou A: The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. Psychopharmacology (Berl) 172:179-186, 2004
169. Fattore L, Cossu G, Martellotta MC, et al: Baclofen antagonizes intravenous self-administration of nicotine in mice and rats. Alcohol Alcohol 37:495-498, 2002
170. Rauhut AS, Mullins SN, Dwoskin LP, et al: Reboxetine: attenuation of intravenous nicotine self-administration in rats. J Pharmacol Exp Ther 303:664-672, 2002
171. Papp M, Gruca P, Willner P: Selective blockade of drug-induced place preference conditioning by ACPC, a functional NDMA-receptor antagonist. Neuropsychopharmacology 27:727-743, 2002
172. Cohen C, Perrault G, Voltz C, et al: SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13:451-463, 2002
173. Shields A, Lerman C, Sullivan P: Translating emerging research on the genetics of smoking into clinical practice: Ethical and social considerations. Nicotine Tob Res 6:675-688, 2004
174. Shields A, Blumenthal D, Weiss K, et al: Barriers to translating genetic research on smoking into clinical practice: Results from a national survey of primary care physicians. J Gen Intern Med: in press